Ben K. Seon - Concepedia

Author

Ben K. Seon

Roswell Park Comprehensive Cancer Center ORCID

Also Known As

B K SEON, B K Seon, B Seon, B-K Seon, B. K. Seon, B. Seon, B.-K Seon, B.-K. Seon, B.K Seon, B.K. Seon

132

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center Tracon Pharmaceuticals (United States)New York State Department of State Duke Medical Center

About

Ben K. Seon is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	39	1.6K
2	Allergy	10	10	267
3	Natural Sciences	7	7	380
4	Biochemistry	7	7	383
5	Health Sciences	2	2	26

Ben K. Seon

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8(CD79b) E Moreau, Estella Matutes, Roger A’Hern, American Journal of Clinical Pathology	1997	401
Disappearance of a structural chromatin protein A24 in mitosis: implications for molecular basis of chromatin condensation. Seiichi Matsui, Ben K. Seon, A.A. Sandberg Proceedings of the National Academy of Sciences Molecular BiologyCytoskeletonCell CycleEpigeneticsCell Division	1979	195
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Clinical Cancer Research	2012	169
Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Ben K. Seon, Fumihiko Matsuno, Yuro Haruta, PubMed Endothelial CellsImmunologyImmunoeditingImmunotherapyTumor Biology	1997	167
Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Norihiko Takahashi, Akinao Haba, Fumihiko Matsuno, PubMed Clinical ImmunologyImmunologyDermatologyImmunotherapyTumor Biology	2001	152
Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Fumihiko Matsuno, Yuro Haruta, Masao Kondo, PubMed Cancer ImmunosurveillanceUnconjugated MabsImmunologyPathologyComplete Regression	1999	145
Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis Chao Li, Razan Gardy, Ben K. Seon, British Journal of Cancer	2003	117
Isopeptidase: a novel eukaryotic enzyme that cleaves isopeptide bonds. Sho Matsui, A.A. Sandberg, Shigeru Negoro, Proceedings of the National Academy of Sciences Protein ChemistryChromatinProtein FunctionCellular EnzymologyBiochemistry	1982	91
Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using125I-labeled anti-endoglin monoclonal antibodies Masahiro Tabata, Masao Kondô, Yuro Haruta, International Journal of Cancer	1999	76
Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature Shima Uneda, Hirofumi Toi, Tomoko Tsujie, International Journal of Cancer	2009	75

Page 1